Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol ...

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused ...

UCB announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency DisorderPhase 3 study met primary and key secondary clinical endpoints, marking the third developmental and ...

Methylergonovine Injection prescription and dosage information for physicians and health care professionals. Pharmacology, adverse reactions, warnings, and Methylergonovine Injectionside effects.

Nafcillin is a CYP3A4 and CYP2C9 inducer and significantly higher maintenance doses of warfarin were required after initiating long-term (>6 weeks) nafcillin treatment. 13, 32, 33 Several case reports ...

The study concluded that strong CYP3A4 inhibitors and inducers should be avoided during treatment with ibrutinib because their significant impact on its pharmacokinetics could lead to AEs from ...

Strong CYP3A4 inhibitors: reduce Revuforj dose Strong or moderate CYP3A4 inducers: avoid concomitant use with Revuforj QTc-prolonging drugs: avoid concomitant use with Revuforj.

Revuforj (revumenib) is an oral, first-in-class, selective menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene ...